{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:09:17Z","timestamp":1776913757890,"version":"3.51.2"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejmech.2019.07.025","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T11:22:18Z","timestamp":1562757738000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Furocoumarins as multi-target agents in the treatment of cystic fibrosis"],"prefix":"10.1016","volume":"180","author":[{"given":"Anna","family":"Carbone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Montalbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Span\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Musante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis J.V.","family":"Galietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Barraja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.07.025_bib1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejmech.2018.04.051","article-title":"Natural oxyprenylated coumarins are modulators of melanogenesis","volume":"152","author":"Fiorito","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2017.06.044","article-title":"New arylpyrazoline-coumarins: synthesis and anti-inflammatory activity","volume":"138","author":"Chen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib3","first-page":"958","article-title":"Synthesis and biological evaluation of coumarin derivatives containing imidazole skeleton as potential antibacterial agents","volume":"143","author":"Wu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejmech.2017.05.004","article-title":"Recent developments of coumarin-containing derivatives and their anti-tubercular activity","volume":"136","author":"Xu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejmech.2016.07.056","article-title":"Therapeutic potential of coumarins as antiviral agents","volume":"123","author":"Hassan","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmech.2018.07.059","article-title":"Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: design, synthesis and antibacterial activity","volume":"157","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2014.07.009","article-title":"Design and synthesis of coumarin-3-acylamino derivatives to scavenge radicals and to protect DNA","volume":"84","author":"Liu","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib8","first-page":"276","article-title":"Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases","volume":"143","author":"Del Prete","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopha.2018.06.053","article-title":"Antioxidant and anti-inflammatory properties of marmelosin from Bael (Aegle marmelos L.); Inhibition of TNF-\u03b1 mediated inflammatory\/tumor markers","volume":"106","author":"Pynam","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2019.07.025_bib10","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/jhet.3318","article-title":"Synthesis of novel anti-inflammatory psoralen derivatives - structures with distinct anti-inflammatory activities","volume":"55","author":"Timonen","year":"2018","journal-title":"J.\u00a0Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/acsmedchemlett.8b00170","article-title":"Targeting tumor associated carbonic anhydrases IX and XII: highly isozyme selective coumarin and psoralen inhibitors","volume":"9","author":"Melis","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.07.025_bib12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1039\/C8RA09755K","article-title":"Preparation of novel 1,2,3-triazole furocoumarin derivatives via click chemistry and their anti-vitiligo activity","volume":"9","author":"Niu","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2019.07.025_bib13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/ijms19030746","article-title":"Novel furocoumarin derivatives stimulate melanogenesis in b16 melanoma cells by up-regulation of mitf and tyr family via Akt\/GSK3\u03b2\/\u03b2-catenin signaling pathways","volume":"19","author":"Niu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2019.07.025_bib14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.bmcl.2018.12.048","article-title":"Synthetically modified methoxsalen for enhanced cytotoxicity in light and dark reactions","volume":"29","author":"Guillon","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.07.025_bib15","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.3892\/mmr.2017.7219","article-title":"Angelicin inhibits liver cancer growth in\u00a0vitro and in\u00a0vivo","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2019.07.025_bib16","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1021\/acs.jmedchem.6b01825","article-title":"Inhibition of the aldehyde dehydrogenase 1\/2 family by psoralen and coumarin derivatives","volume":"60","author":"Buchman","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1021\/jm3013486","article-title":"Identification and characterization of new DNA G-quadruplex binders selected by a combination of ligand and structure-based virtual screening approaches","volume":"56","author":"Costa","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2014.07.008","article-title":"Novel furocoumarins as potential HIV-1 integrase inhibitors","volume":"57","author":"Olomola","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/jm901570x","article-title":"Anti-influenza drug discovery: structure\u2212Activity relationship and mechanistic insight into novel angelicin derivatives","volume":"53","author":"Chang","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bmcl.2015.11.056","article-title":"Synthesis and fluorescent study of 5-phenyl furocoumarin derivatives as vasodilatory agents","volume":"26","author":"Wang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.07.025_bib21","doi-asserted-by":"crossref","first-page":"8619","DOI":"10.3892\/mmr.2017.7706","article-title":"Imperatorin possesses notable anti-inflammatory activity in\u00a0vitro and in\u00a0vivo through inhibition of the NF-\u03baB pathway","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2019.07.025_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jep.2017.03.033","article-title":"Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1\u03b1 via the mTOR\/p70S6K\/4E-BP1 and MAPK pathways","volume":"203","author":"Mi","year":"2017","journal-title":"J.\u00a0Ethnopharmacol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s11101-016-9456-2","article-title":"Imperatorin\u2013pharmacological meaning and analytical clues: profound investigation","volume":"15","author":"Kozio\u0142","year":"2016","journal-title":"Phytochemistry Rev."},{"key":"10.1016\/j.ejmech.2019.07.025_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejmech.2017.08.070","article-title":"Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents","volume":"142","author":"Dichiara","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejmech.2005.10.016","article-title":"Psoralen analogues: synthesis, inhibitory activity of growth of human tumor cell lines and computational studies","volume":"41","author":"Afonso","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejps.2018.08.031","article-title":"The active compounds derived from Psoralea corylifolia for photochemotherapy against psoriasis-like lesions: the relationship between structure and percutaneous absorption","volume":"124","author":"Alalaiwe","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2019.07.025_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1011-1344(02)00332-9","article-title":"Apoptosis in leukocytes induced by UVA in the presence of 8-methoxypsoralen, chlorpromazine or 4,6,4\u2032-trimethylangelicin","volume":"68","author":"Wolnicka-G\u0142ubisz","year":"2002","journal-title":"J.\u00a0Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/1011-1344(94)07040-7","article-title":"4,6,4\u2032-Trimethylangelicin induces interstrand cross-links in mammalian cell DNA","volume":"26","author":"Bordin","year":"1994","journal-title":"J.\u00a0Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.tips.2007.05.004","article-title":"Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis","volume":"28","author":"Amaral","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2019.07.025_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10545-006-0251-x","article-title":"Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease","volume":"29","author":"Amaral","year":"2006","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmech.2019.07.025_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jcf.2005.12.003","article-title":"Dysregulated interleukin-8 secretion and NF-kB activity in human cystic fibrosis nasal epithelial cells","volume":"5","author":"Carrabino","year":"2006","journal-title":"J.\u00a0Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2019.07.025_bib32","first-page":"346","article-title":"The NF\u03baB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential","volume":"9","author":"Bodas","year":"2010","journal-title":"Discov. Med."},{"key":"10.1016\/j.ejmech.2019.07.025_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/0092-8674(86)90807-X","article-title":"Lnducibility of k lmmunoglobulin enhancer-binding protein NF-kB by a posttranslational mechanism","volume":"47","author":"Sen","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.07.025_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a000034","article-title":"The NF- k B family of transcription factors and its regulation","volume":"1","author":"Oeckinghaus","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00109-004-0555-y","article-title":"Nuclear factor-kappaB\u202f: its role in health and disease","volume":"82","author":"Kumar","year":"2004","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.ejmech.2019.07.025_bib36","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.intimp.2009.08.013","article-title":"Modulation of expression of IL-8 gene in bronchial epithelial cells by","volume":"9","author":"Nicolis","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib37","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1016\/j.bmc.2010.09.063","article-title":"Virtual screening against nuclear factor kB ( NF-kB ) of a focus library\u202f: identification of bioactive furocoumarin derivatives inhibiting NF-kB dependent biological functions involved in cystic fibrosis","volume":"18","author":"Piccagli","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib38","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cmdc.200900362","article-title":"Virtual screening against p50 NF-\u03baB transcription factor for the identification of inhibitors of the NF-\u03baB-DNA interaction and expression of NF-\u03baB upregulated genes","volume":"4","author":"Piccagli","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.07.025_bib39","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1016\/j.ejmech.2011.07.032","article-title":"Development of a novel furocoumarin derivative inhibiting NF- k B dependent biological functions\u202f: design , synthesis and biological effects","volume":"46","author":"Borgatti","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib40","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1021\/jm3009647","article-title":"Psoralen derivatives as inhibitors of NF-\u03baB\/DNA interaction: synthesis, molecular modeling, 3D-QSAR, and biological evaluation","volume":"56","author":"Marzaro","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1152\/ajplung.00129.2010","article-title":"Trimethylangelicin reduces IL-8 transcription and potentiates CFTR function","volume":"300","author":"Tamanini","year":"2011","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1152\/ajplung.00305.2013","article-title":"Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells","volume":"307","author":"Favia","year":"2014","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2389487","article-title":"Differential effects of angelicin analogues on NF- \u03baB activity and IL-8 gene expression in cystic fibrosis IB3-1 cells","volume":"2017","author":"Lampronti","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2019.07.025_bib44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejmech.2018.03.080","article-title":"Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB ( NF-kB )","volume":"151","author":"Marzaro","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.07.025_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11030-015-9586-2","article-title":"Psoralen derivatives as inhibitors of NF-\u03baB\/DNA interaction: the critical role of the furan ring","volume":"19","author":"Marzaro","year":"2015","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2019.07.025_bib46","doi-asserted-by":"crossref","first-page":"C976","DOI":"10.1152\/ajpcell.1997.272.3.C976","article-title":"Psoralens- novel modulators of Cl- secretion","volume":"272","author":"Devor","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib47","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1440-1681.2008.04943.x","article-title":"Identification of natural coumarin compounds that rescue defective DF508-CFTR chloride channel gating","volume":"35","author":"Xu","year":"2008","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2011.00052","article-title":"Stimulation of airway and intestinal mucosal secretion by natural coumarin CFTR activators","volume":"2","author":"Yang","year":"2011","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib49","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in\u00a0vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2019.07.025_bib50","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/mol.118.111799","article-title":"Correctors of the major Cystic Fibrosis mutant interact through membrane spanning domains","volume":"93","author":"Laselva","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/mol.117.108373","article-title":"Direct binding of the corrector VX-809 to human CFTR NBD1: evidence of an allosteric coupling between the binding site and the NBD1:CL4 interface","volume":"92","author":"Hudson","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib52","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmech.2019.07.025_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2016.09.005","article-title":"The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain","volume":"119","author":"Laselva","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.07.025_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.00719","article-title":"Molecular mechanism of action of trimethylangelicin derivatives as CFTR modulators","volume":"9","author":"Laselva","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:57:36Z","timestamp":1759327056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419306464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":54,"alternative-id":["S0223523419306464"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.07.025","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Furocoumarins as multi-target agents in the treatment of cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}